Communiqués Pelthos Therapeutics Inc.

Actions

PTHS

US1711262048

Produits pharmaceutiques

Marché Fermé - NYSE 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
21,01 ^USD	+0,43 %		-10,67 %	-32,23 %

14/08	Pelthos Therapeutics Inc. : Oppenheimer réitère son opinion positive sur le titre	ZM
13/08	Transcript : Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026

Communiqués

13/08	Pelthos Therapeutics Announces Second Quarter 2026 Financial Results	AQ
03/08	Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026	AQ
27/07	Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders	AQ
24/07	Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders	AQ
30/06	Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes	AQ
28/05	Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference	AQ
14/05	Pelthos Therapeutics : Investor Presentation (Investment Deck 2026.05 vF)	PU
14/05	Pelthos Therapeutics Announces First Quarter 2026 Financial Results	AQ
01/05	Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026	AQ
14/04	Pelthos Therapeutics : Investor Presentation (Final Investment Deck 2026.04)	PU
14/04	Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium	AQ
10/04	Pelthos Therapeutics Announces CFO Transition	AQ
31/03	Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain	AQ
19/03	Pelthos Therapeutics : Investor Presentation (Final Investment Deck 2026.03R)	PU
19/03	Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results	AQ
12/03	Pelthos Therapeutics to Present at 38th Annual ROTH Conference	AQ
09/03	Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026	AQ
23/02	Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
15/01	Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics	BU
12/01	Pelthos Therapeutics : Investor Presentation (Investment Deck 2026.01.V2)	PU
05/01	Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice	AQ
23/12	Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn	AQ
05/12	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI Topical Gel, 10.3%	AQ
04/12	Pelthos Therapeutics : Investor Presentation (Investment Deck 2025.12)	PU
04/12	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%	AQ